Literature DB >> 10864183

Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis.

M L Joloba1, J L Johnson, A Namale, A Morrissey, A E Assegghai, R D Mugerwa, J J Ellner, K D Eisenach.   

Abstract

SETTING: National Tuberculosis (TB) Treatment Centre, Mulago Hospital and Joint Clinical Research Centre, Kampala, Uganda.
OBJECTIVE: To compare the quantitative sputum bacillary load between TB patients infected with the human immunodeficiency virus (HIV) and those non-infected, during treatment with standard short course chemotherapy (SCC).
DESIGN: To compare clinical characteristics and quantitative sputum bacillary load as measured by quantitative acid-fast bacilli (AFB) smears, colony forming unit (cfu) assay and time until positive culture in the BACTEC radiometric liquid system between 14 HIV-infected and 22 non-HIV-infected adults with initial episodes of smear-positive pulmonary TB at baseline and during treatment with standard four-drug SCC.
RESULTS: Other than cavitation (P = 0.042) and adenopathy (P = 0.03), which were more common among non-HIV-infected and HIV-infected patients, respectively, there were no significant differences in baseline demographic, clinical, radiological and laboratory characteristics between the groups. Mean pretreatment sputum bacillary burden (6.5+/-0.51 log10 AFB/ml, 5.91+/-0.91 log10 cfu/ml and 1.8+/-1.7 days until positive BACTEC culture for HIV-infected patients and 6.32+/-0.85 log10 AFB/ml, 5.58+/-0.68 log10 cfu/ml and 1+/-1.2 days until positive BACTC culture for non-HIV-infected patients) were comparable between HIV-infected and non-HIV-infected patients. Clinical and bacteriological responses to standard SCC and treatment outcome did not differ between the groups.
CONCLUSION: Quantitative sputum bacillary load at baseline and during SCC did not differ significantly between HIV-infected and non-HIV-infected adults with initial episodes of smear-positive TB.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864183

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  15 in total

1.  Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.

Authors:  Marc Weiner; Thomas J Prihoda; William Burman; John L Johnson; Stefan Goldberg; Nesri Padayatchi; Paula Duran; Melissa Engle; Grace Muzanye; Roy D Mugerwa; A Willem Sturm
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

2.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

3.  Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment.

Authors:  Geraint R Davies; Richard Brindle; Saye H Khoo; Leon J Aarons
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

4.  A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.

Authors:  Sebabrata Mahapatra; Lisa K Woolhiser; Anne J Lenaerts; John L Johnson; Kathleen D Eisenach; Moses L Joloba; W Henry Boom; John T Belisle
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

5.  Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures.

Authors:  C M Bark; A Okwera; M L Joloba; B A Thiel; J G Nakibali; S M Debanne; W H Boom; K D Eisenach; J L Johnson
Journal:  Tuberculosis (Edinb)       Date:  2011-02-25       Impact factor: 3.131

6.  Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression.

Authors:  Colleen F Hanrahan; Grant Theron; Jean Bassett; Keertan Dheda; Lesley Scott; Wendy Stevens; Ian Sanne; Annelies Van Rie
Journal:  Am J Respir Crit Care Med       Date:  2014-06-01       Impact factor: 21.405

7.  Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.

Authors:  William R Mac Kenzie; Charles M Heilig; Lorna Bozeman; John L Johnson; Grace Muzanye; Denise Dunbar; Kenneth C Jost; Lois Diem; Beverly Metchock; Kathleen Eisenach; Susan Dorman; Stefan Goldberg
Journal:  PLoS One       Date:  2011-04-11       Impact factor: 3.240

8.  Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients.

Authors:  Gang Sun; Tao Luo; Chongguang Yang; Xinran Dong; Jing Li; Yongqiang Zhu; Huajun Zheng; Weidong Tian; Shengyue Wang; Clifton E Barry; Jian Mei; Qian Gao
Journal:  J Infect Dis       Date:  2012-09-14       Impact factor: 5.226

9.  Deoxyribozyme cascade for visual detection of bacterial RNA.

Authors:  Yulia V Gerasimova; Evan M Cornett; Emily Edwards; Xiaoli Su; Kyle H Rohde; Dmitry M Kolpashchikov
Journal:  Chembiochem       Date:  2013-09-17       Impact factor: 3.164

10.  Comparing rates of mycobacterial clearance in sputum smear-negative and smear-positive adults living with HIV.

Authors:  Edith E Machowski; Matebogo Letutu; Limakatso Lebina; Ziyaad Waja; Reginah Msandiwa; Minja Milovanovic; Bhavna G Gordhan; Kennedy Otwombe; Sven O Friedrich; Richard Chaisson; Andreas H Diacon; Bavesh Kana; Neil Martinson
Journal:  BMC Infect Dis       Date:  2021-05-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.